Lanean...
DDIS-12. ONC201: THE FIRST SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONIST FOR CLINICAL NEURO-ONCOLOGY
ONC201 has exhibited preliminary clinical evidence of anti-tumor activity and safety in high grade glioma patients. In this study, we identified and characterized a previously unknown binding target of ONC201. BANDIT – a machine learning-based target identification platform – predicted that ONC201 w...
Gorde:
| Argitaratua izan da: | Neuro Oncol |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216563/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.291 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|